var data={"title":"Erythromycin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Erythromycin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/211421?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=erythromycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Erythromycin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=erythromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Erythromycin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086256\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>E.E.S. 400;</li>\n      <li>E.E.S. Granules;</li>\n      <li>Ery-Tab;</li>\n      <li>EryPed 200;</li>\n      <li>EryPed 400;</li>\n      <li>Erythrocin Lactobionate;</li>\n      <li>Erythrocin Stearate;</li>\n      <li>PCE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086257\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>EES;</li>\n      <li>Erybid;</li>\n      <li>Eryc;</li>\n      <li>Erythrocin;</li>\n      <li>PCE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10484225\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Macrolide</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442462\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>General dosing:</b> Oral (ethylsuccinate); IV (lactobionate): (<i>Red Book</i>, 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Body weight &lt;1 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;14 days: 10 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 15-28 days: 10 mg/kg/dose every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Body weight 1-2 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\"> PNA &le;7 days: 10 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8-28 days: 10 mg/kg/dose every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bodyweight &gt;2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &le;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 8-28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chlamydial conjunctivitis or chlamydial pneumonia:</b> Oral: Ethylsuccinate or base: Full-term neonates: 50 mg/kg/<b>day</b> divided every 6 hours for 14 days; a repeat course may be necessary (<i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pertussis; treatment or postexposure prophylaxis:</b> Oral: Ethylsuccinate: 10 mg/kg/dose 4 times daily for 14 days; <b>Note:</b> Due to association of erythromycin and infantile hypertrophic pyloric stenosis in neonates, azithromycin is considered first-line agent in infants &lt;1 month of age (<i>Red Book</i>, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prokinetic (GI motility) agent:</b> Limited data available; efficacy results variable: PNA &ge;14 days:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Low-dose regimen: Oral: 1.5-2.5 mg/kg/dose every 6 hours; therapy started after initiation of enteral feeds; has been studied in GA &lt;32 weeks (Chicella, 2005; Oei, 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intermediate-dose regimen: Oral: 5 mg/kg/dose every 6 hours; therapy started after initiation of enteral feeds; dosing based on a randomized, controlled trial of 45 VLBW neonates (n=19 treatment group; mean GA: 28.4 weeks); treatment was initiated at a mean PNA: 21.9 + 7.7 days and continued for 14 days (Ng, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">High-dose regimens (antimicrobial doses): Oral: 10-12.5 mg/kg/dose every 6-8 hours orally have been used after initiation of enteral feeds; efficacy has not been demonstrated in the majority of trials. Exposure to these doses in neonates with PNA &le;14 days has been associated with a 10-fold increase in the risk of hypertrophic pyloric stenosis (Chicella, 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485224\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=erythromycin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Erythromycin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Base, ethylsuccinate, stearate: 30 to 50 mg/kg/<b>day</b> divided every 6 to 8 hours usually; for severe infection may double dose; maximum daily dose: Mild to moderate infection: 2,000 mg/<b>day</b>; severe infection: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Lactobionate: 15 to 20 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (<i>Red Book</i> 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate infection: Oral: 50 mg/kg/<b>day</b> divided every 6 to 8 hours; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe infection: IV: Lactobionate: 5 mg/kg/dose every 6 hours, maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne, moderate to severe; treatment:</b> Children and Adolescents: Oral: 250 to 500 mg 1 to 2 times daily in conjunction with topical therapy (eg, benzoyl peroxide); maximum daily dose: 50 mg/kg/<b>day</b>; duration of 4 to 8 weeks of therapy usually necessary to evaluate initial clinical response with a longer duration for a maximum effect (3 to 6 months); resistance problematic with therapy, use typically reserved for patients &lt;8 years who cannot receive tetracycline derivatives (Eichenfield 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax, cutaneous, community-acquired</b> (Stevens 2005): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 10 mg/kg/dose every 6 hours; treatment duration of 5 to 9 days usually adequate in most cases</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 20 to 40 mg/kg/<b>day</b> divided every 6 hours; maximum daily dose: 4,000 mg; treatment duration of 5 to 9 days usually adequate in most cases</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Bartonella</i> sp infections [bacillary angiomatosis (BA), peliosis hepatis (PH)]:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive; treatment: Infants, Children, and Adolescents: Oral: Ethylsuccinate: 10 mg/kg/ dose 4 times daily; maximum daily dose: 2,000 mg/day; treatment duration: BA: 3 months; PH: 4 months (Rolain 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prophylaxis: Infants and Children (CDC 2009): Oral: 30 to 50 mg/kg/day divided into 2 to 4 doses daily; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment: Duration of therapy: &ge;3 months (of sufficient duration to prevent relapse)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children (CDC 2009): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Oral: 30 to 50 mg/kg/day divided into 2 to 4 doses daily; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IV: 15 to 50 mg/kg/day divided into 4 doses daily; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: IV, Oral: 500 mg every 6 hours with or without rifampin (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infants, Children, and Adolescents: Oral (base): 30 to 50 mg/kg/<b>day</b> divided 3 to 4 times daily; maximum dose: 500 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Chlamydia trachomatis</i> infection</b> (CDC 2010; <i>Red Book</i> 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conjunctivitis or pneumonia: Infants, Children, and Adolescents: Oral (base or ethylsuccinate): 50 mg/kg/<b>day</b> divided every 6 hours for 14 days; maximum daily dose: 2,000 mg/<b>day</b>; a repeat course may be necessary; for severe trachoma, longer durations may be necessary (40 days) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anogenital tract infection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;45 kg: Oral (base or ethylsuccinate): 50 mg/kg/<b>day</b> divided every 6 hours for 14 days; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;45 kg: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Base: 500 mg 4 times daily for 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Ethylsuccinate: 800 mg 4 times daily for 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lymphogranuloma venereum (LGV): Adolescents &ge;45 kg: Oral (base): 500 mg 4 times daily for 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Impetigo:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose 4 times daily (Stevens 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lyme Disease:</b> Infants, Children, and Adolescents: Oral: 50 mg/kg/day divided every 6 hours for 14 to 21 days; maximum dose: 500 mg (Wormser 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pertussis</b> (CDC 2005; <i>Red Book</i> 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 1 to 5 months: Oral: 10 mg/kg/dose 4 times daily for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children: Oral: 10 mg/kg/dose 4 times daily for 7 to 14 days; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 500 mg 4 times daily for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired (CAP)</b> (Bradley 2011): Infants &gt;3 months, Children, and Adolescents: <b>Note:</b> A beta-lactam antibiotic should be added if typical bacterial pneumonia cannot be ruled out. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presumed atypical (<i>M. pneumoniae, C. pneumoniae, C. trachomatis</i>); mild infection or step-down therapy: Oral: 10 mg/kg/dose every 6 hours; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe atypical infection: IV: Lactobionate: 5 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preoperative bowel preparation:</b> Children and Adolescents: Oral: Base: 20 mg/kg; maximum dose: 1,000 mg administered at 1, 2, and 11 PM on the day before surgery combined with mechanical cleansing of the large intestine and oral neomycin (Bratzler 2013) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prokinetic (GI motility) agent:</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Diagnosis; gastric emptying study (provocative testing): IV: 2.8 mg/kg infused over 20 minutes was reported from one center's experience; maximum dose: 250 mg (Waseem 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Oral: 3 mg/kg/dose 4 times daily; may increase as needed to effect; maximum dose: 10 mg/kg or 250 mg (Rodriguez 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumococcal, prophylaxis in penicillin-allergic patients with sickle cell disease (SCD) and functional or anatomic asplenia</b> (Knight-Madden 2001): Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: 4 months to &lt;3 years: 125 mg twice daily; salt not specified </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to 4 years: 250 mg twice daily; salt not specified </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing: Note:</b> Due to differences in absorption, 400 mg erythromycin ethylsuccinate produces the same serum levels as 250 mg erythromycin base or stearate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Lactobionate: 15 to 20 mg/kg/day divided every 6 hours or given as a continuous infusion over 24 hours, not to exceed 4 g/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Base, delayed release: 333 mg every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Stearate or base: 250 to 500 mg every 6 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ethylsuccinate: 400 to 800 mg every 6 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chancroid:</b> Oral: Base: 500 mg 3 times/day for 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Chlamydia trachomatis:</i></b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Base: 500 mg 4 times/day for 7 days <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ethylsuccinate: 800 mg 4 times/day for 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pertussis:</b> Oral: 500 mg every 6 hours for 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preoperative bowel preparation:</b> Oral: 1 g erythromycin base at 1, 2, and 11 PM on the day before surgery combined with mechanical cleansing of the large intestine and oral neomycin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff 2007). <b>Note:</b> Renally adjusted dose recommendations are based on oral doses of 30 to 50 mg/kg/<b>day</b> divided every 6 to 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &ge;10 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Intermittent hemodialysis, peritoneal dialysis: Not removed by peritoneal dialysis or hemodialysis: 10 to 17 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086458\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release Particles, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as lactobionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erythrocin Lactobionate: 500 mg (1 ea); 1000 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as ethylsuccinate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">E.E.S. Granules: 200 mg/5 mL (100 mL, 200 mL) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EryPed 200: 200 mg/5 mL (100 mL) [fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EryPed 400: 400 mg/5 mL (100 mL) [banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/5 mL (100 mL, 200 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as ethylsuccinate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">E.E.S. 400: 400 mg [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as stearate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erythrocin Stearate: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ery-Tab: 250 mg, 333 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PCE: 333 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PCE: 500 mg [dye free, no artificial color(s)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086259\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485264\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:  Administer base, PCE, or stearate dosage forms on an empty stomach (2 hours before or after a meal); administer ethylsuccinate (EES) or delayed-release (ERY-TAB)  without regards to meals; may consider administering after food to decrease GI discomfort. Swallow delayed release capsule or enteric coated tablets whole, do not chew or break </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by intermittent IV infusion over 20 to 60 minutes or as a continuous infusion. Intermittent IV infusion may be very irritating to the vein; per the manufacturer, continuous infusion is preferable due to slower infusion rate and lower concentration. For intermittent IV infusion, prolonging the infusion duration over 60 minutes or longer has been recommended to decrease the cardiotoxic effects of erythromycin (Farrar 1993; Sims 1994). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086365\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store unreconstituted vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solution (50 mg/mL) is stable for 2 weeks when refrigerated or for 24 hours at room temperature. Erythromycin IV infusion solution is stable at pH 6 to 8; stability of lactobionate is pH dependent; IV form has longest stability in NS. Parenteral admixture in NS is stable for 24 hours at 4&deg;C. Admixtures in NS (including Add-Vantage containers)  should be infused within 8 hours of preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Granules: Prior to mixing, store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). After mixing, store under refrigeration and use within 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder: Prior to mixing, store at &lt;30&deg;C (86&deg;F). After mixing, store at &le;25&deg;C (77&deg;F) and use within 35 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet and capsule formulations: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485164\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of mild to moderately severe infections of the upper and lower respiratory tract and skin infections due to susceptible <i>streptococcus</i> and <i>staphylococcus</i> sp. and <i>Haemophilus influenzae</i>; other susceptible bacterial infections, including <i>Mycoplasma pneumoniae</i>, <i>Legionella pneumonia</i>, nongonococcal urethritis, Lyme disease, diphtheria, pertussis, chancroid, <i>Chlamydia</i>, <i>Ureaplasma</i>, and <i>Campylobacter</i> gastroenteritis, syphilis, prophylaxis of recurrent rheumatic fever in penicillin- or sulfa-allergic patients (all indications: FDA approved in all ages); has also been used in conjunction with neomycin for decontaminating the bowel for surgery; prophylaxis of pneumococcal infections in children with sickle cell disease (SCD), and functional or anatomic asplenia who are penicillin allergic; treatment of exit-site or tunnel infection in patients with peritoneal dialysis catheters</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8085309\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erythromycin may be confused with azithromycin, clarithromycin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eryc may be confused with Emcyt, Ery-Tab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086286\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Local thrombophlebitis, prolonged Q-T interval on ECG, torsades de pointes, ventricular arrhythmia, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema multiforme, pruritus, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, pyloric stenosis (infantile hypertrophic), vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Abnormal hepatic function tests, cholestatic jaundice (most common with estolate), hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Interstitial nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Hepatotoxicity (idiosyncratic) (Chalasani, 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086273\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to erythromycin, any macrolide antibiotics, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concomitant use with pimozide, cisapride, ergotamine or dihydroergotamine, terfenadine, astemizole, lovastatin, or simvastatin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086274\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: Macrolides have been associated with rare QTc prolongation and ventricular arrhythmias, including torsade de pointes; use with caution in patients at risk of prolonged cardiac repolarization; avoid use in patients with prolonged QT interval, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or concurrent use of Class IA (eg, quinidine, procainamide) or Class III (eg, amiodarone, dofetilide, sotalol) antiarrhythmic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with preexisting liver disease; hepatic impairment, including hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been observed. Discontinue if symptoms of malaise, nausea, vomiting, abdominal colic, and fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Exacerbation of and new onset of myasthenia gravis symptoms have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Major inhibitor of CYP3A4: Use caution with any agents with substantial metabolism through the CYP3A4 pathway; high potential for drug interactions exists. Avoid concurrent use with strong CYP3A4 inhibitors; may increase the risk of sudden cardiac death (Ray 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants: Use of erythromycin has been associated with infantile hypertrophic pyloric stenosis (IHPS); observe for non-bilious vomiting or irritability with feeding. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: May be at increased risk of adverse events, including hearing loss and/or torsade de pointes, particularly if concurrent renal/hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage form specific issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872268\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Hepatic impairment with or without jaundice has occurred primarily in older children and adults; reported incidence in children is ~0.1% and in adults is 0.25%; it may be accompanied by malaise, nausea, vomiting, abdominal colic, and fever; discontinue use if these occur. Infantile hypertrophic pyloric stenosis with symptoms of nonbilious vomiting or irritability with feeding has been reported in 5% of infants who received erythromycin for pertussis prophylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086288\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (moderate), P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086289\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15977&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: Erythromycin (Systemic) may increase the serum concentration of Alfentanil.  Management: For patients who are actively receiving erythromycin, caution should be used in administering alfentanil; monitor for increased anesthetic and respiratory depressant effects. Consider using lower doses of alfentanil or an alternative anesthetic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALPRAZolam: Erythromycin (Systemic) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amdinocillin: Erythromycin (Systemic) may diminish the therapeutic effect of Amdinocillin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antineoplastic Agents (Vinca Alkaloids): Macrolide Antibiotics may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues.  Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: Erythromycin (Systemic) may increase the serum concentration of AtorvaSTATin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: Erythromycin (Systemic) may increase the serum concentration of Barnidipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: Erythromycin (Systemic) may increase the serum concentration of BusPIRone.  Management: Limit the buspirone dose to 2.5 mg twice daily and monitor for increased buspirone effects/toxicities if combined with erythromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Macrolide Antibiotics may decrease the metabolism of Calcium Channel Blockers.  Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Erythromycin (Systemic) may increase the serum concentration of CarBAMazepine.  Management: Consider alternative antimicrobial therapy in combination with carbamazepine. If combined, monitor for increased carbamazepine effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Macrolide Antibiotics may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Macrolide Antibiotics may enhance the QTc-prolonging effect of Cisapride. Macrolide Antibiotics may decrease the metabolism of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): Erythromycin (Systemic) may diminish the therapeutic effect of Clindamycin (Topical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Erythromycin (Systemic) may diminish the antiplatelet effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Erythromycin (Systemic) may enhance the adverse/toxic effect of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Erythromycin (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Disopyramide. Macrolide Antibiotics may decrease the metabolism of Disopyramide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Erythromycin (Systemic) may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations vary by indication and international labeling. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Macrolide Antibiotics may increase the serum concentration of Ergot Derivatives. Cabergoline and Clarithromycin may interact, see specific monograph for full details. <b> Exceptions: </b>Cabergoline; Nicergoline; Pergolide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estazolam: Macrolide Antibiotics may increase the serum concentration of Estazolam.  Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased. Management: For the treatment of <i>Mycobacterium avium</i> complex, consider changing to alternative agent, such as azithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: Erythromycin (Systemic) may increase the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May enhance the QTc-prolonging effect of Erythromycin (Systemic). Fluconazole may increase the serum concentration of Erythromycin (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 140 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincomycin: Erythromycin (Systemic) may diminish the therapeutic effect of Lincomycin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: Erythromycin (Systemic) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Erythromycin (Systemic) may enhance the arrhythmogenic effect of Mequitazine.  Management: Concurrent administration of intravenous erythromycin with mequitazine is contraindicated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: Macrolide Antibiotics may increase the serum concentration of Midazolam.  Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: Macrolide Antibiotics may increase the serum concentration of Mizolastine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inhibitors of CYP3A4 and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: Macrolide Antibiotics may enhance the QTc-prolonging effect of Pimozide. Macrolide Antibiotics may decrease the metabolism of Pimozide. This mechanism may not apply to azithromycin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitavastatin: Erythromycin (Systemic) may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin to a maximum of 1 mg/day (adult dose) when used in combination with erythromycin.  If this combination is used, monitor patients more closely for evidence of pitavastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: Erythromycin (Systemic) may increase the serum concentration of Pravastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Erythromycin (Systemic) may enhance the QTc-prolonging effect of QuiNIDine. Erythromycin (Systemic) may increase the serum concentration of QuiNIDine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Macrolide Antibiotics may increase the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: Erythromycin (Systemic) may increase the serum concentration of Repaglinide.  Management: The addition of a CYP2C8 inhibitor to this drug combination may substantially increase the magnitude of increase in repaglinide exposure.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: Macrolide Antibiotics may decrease the metabolism of Rifamycin Derivatives. <b> Exceptions: </b>Rifapentine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Macrolide Antibiotics may increase the serum concentration of Rilpivirine.  Management: Consider the use of azithromycin or another non-macrolide alternative when appropriate to avoid this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Erythromycin (Systemic) may increase the serum concentration of Rivaroxaban.  Management: In patients with impaired renal function, erythromycin should not be used unless the potential benefits outweigh the potential risks. This interaction is unlikely clinically significant in patients with normal renal function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: Erythromycin (Systemic) may enhance the adverse/toxic effect of Sertraline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: Erythromycin (Systemic) may increase the serum concentration of Sildenafil.  Management: For pulmonary arterial hypertension, US label recommends no dose adjustment and Canadian label recommends reducing to 20mg twice/day.  For erectile dysfunction, consider using a lower starting dose of 25mg in patients who are also taking erythromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Erythromycin (Systemic) may increase the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Erythromycin (Systemic) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Erythromycin (Systemic) may increase the serum concentration of Sirolimus. Sirolimus may increase the serum concentration of Erythromycin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Erythromycin (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Macrolide Antibiotics may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Erythromycin (Systemic). Erythromycin (Systemic) may increase the serum concentration of Telaprevir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terfenadine: Macrolide Antibiotics may enhance the QTc-prolonging effect of Terfenadine. Macrolide Antibiotics may increase the serum concentration of Terfenadine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triazolam: Erythromycin (Systemic) may increase the serum concentration of Triazolam.  Management: Consider alternatives to the combination of triazolam and erythromycin. If combined, use extra caution and closer monitoring for excessive triazolam effects. Reduced triazolam doses may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vardenafil: Erythromycin (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit dose of vardenafil film-coated tablets (Levitra)  to 5 mg per 24 hours with concomitant use of erythromycin. Concomitant use of vardenafil orally disintegrating tablets (Staxyn) with erythromycin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Macrolide Antibiotics may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: Erythromycin (Systemic) may decrease the serum concentration of Zafirlukast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086293\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Ethanol may decrease absorption of erythromycin or enhance effects of ethanol. Management: Avoid ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Erythromycin serum levels may be altered if taken with food (formulation-dependent). GI upset, including diarrhea, is common. Management: May be taken with food to decrease GI upset, otherwise take around-the-clock with a full glass of water. Do not give with milk or acidic beverages (eg, soda, juice).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086263\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086264\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Erythromycin crosses the placenta and low concentrations are found in the fetal serum. Cardiovascular anomalies following exposure in early pregnancy have been reported in some observational studies. Serum concentrations of erythromycin may be variable in pregnant women (Kiefer 1955; Philipson 1976). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In patients with acute infections during pregnancy, erythromycin may be given if an antibiotic is required and appropriate based on bacterial sensitivity (ACOG No. 120 2011). Erythromycin is the antibiotic of choice for preterm premature rupture of membranes (with membrane rupture between 24 0/7 to 33 6/7 weeks gestation) (ACOG 2013), the treatment of lymphogranuloma venereum in pregnancy, and the treatment of or long-term suppression of Bartonella infection in HIV-infected pregnant patients. Erythromycin is one of the antibiotics that may be used for the treatment of chancroid or granuloma inguinale and during pregnancy, and may be appropriate as an alternative agent for the treatment of chlamydial infections in pregnant women (consult current guidelines) (CDC [Workowski 2015]; HHS [opportunistic; adult] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485265\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Assess results of culture and sensitivity tests and patient's previous allergy history prior to therapy; liver function tests, observe for changes in bowel frequency; with IV use: Blood pressure, heart rate </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086369\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086371\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Variable but better with salt forms than with base form; 18% to 45%; ethylsuccinate may be better absorbed with food (Thompson 1980).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: 0.64 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion from blood into CSF: Minimal even with inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Normal meninges: 2% to 13%; Inflamed meninges: 7% to 25%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Base: 73% to 81%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Demethylation primarily via hepatic CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Neonates (&le;15 days of age): 2.1 hours; Adults: Peak: 1.5-2 hours; End-stage renal disease: 5-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Base: 4 hours; Ethylsuccinate: 0.5-2.5 hours; Stearate: 3 hours (Steigbigel 2000); delayed with food due to differences in absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces; urine (2% to 15% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8086461\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Erythromycin Base Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $603.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Erythrocin Lactobionate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $91.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (E.E.S. Granules Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (100 mL): $451.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (EryPed 200 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (100 mL): $451.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (EryPed 400 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/5 mL (100 mL): $793.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Erythromycin Ethylsuccinate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/5 mL (100 mL): $390.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Ery-Tab Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $264.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">333 mg (30): $333.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $410.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (PCE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">333 mg (60): $1,163.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $1,525.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (E.E.S. 400 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $1,460.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Erythrocin Stearate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,312.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Erythromycin Base Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,322.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $1,994.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Erythromycin Ethylsuccinate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $1,460.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962015\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abboticin (DK);</li>\n      <li>Abomacetin (JP);</li>\n      <li>Ai Jia Xing (CN);</li>\n      <li>Aldricin (PH);</li>\n      <li>Ambamida (AR);</li>\n      <li>Ao Shu Xin (CN);</li>\n      <li>Baknyl (EC);</li>\n      <li>Dothrocyn (ID);</li>\n      <li>E-Mycin (AU, PK);</li>\n      <li>Ecolide (PH);</li>\n      <li>EES (AU);</li>\n      <li>Emu-V E (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>ERA (NZ);</li>\n      <li>Erase (IN);</li>\n      <li>Eribiotic (BR);</li>\n      <li>Erigran (PY);</li>\n      <li>Erios (CH);</li>\n      <li>Eritrex (BR);</li>\n      <li>Eritrocina (PT);</li>\n      <li>Eritrolag (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Eritromicin (HR);</li>\n      <li>Eritromicina (CL, CU);</li>\n      <li>Ermycin (CY, MT, SG, TR);</li>\n      <li>ERO-125 (TZ);</li>\n      <li>Erocin (BD);</li>\n      <li>Eromel (ZA, ZW);</li>\n      <li>Eromycin (KW);</li>\n      <li>Erotab (SG);</li>\n      <li>Ery (DE);</li>\n      <li>Ery Max (IS);</li>\n      <li>Ery-Diolan (QA);</li>\n      <li>Ery-Tab (BB, BM, BS, BZ, GY, JM, PR, SR, TT);</li>\n      <li>Eryc (KR, KW, QA, SA);</li>\n      <li>Erycin (ET, MY, TH, TW);</li>\n      <li>Erycip (LK);</li>\n      <li>Eryest (ZW);</li>\n      <li>Eryko (LK);</li>\n      <li>Erymax (IE);</li>\n      <li>Erymer (LK);</li>\n      <li>Erymycin AF (ZA);</li>\n      <li>Eryped 200 (BB);</li>\n      <li>Eryped 400 (BB);</li>\n      <li>Erysanbe (ID);</li>\n      <li>Erytab-S (MY);</li>\n      <li>Eryth-Mycin (TH);</li>\n      <li>Erythin (BD);</li>\n      <li>Erythran (TR);</li>\n      <li>Erythro (KR);</li>\n      <li>Erythro-Teva (IL);</li>\n      <li>Erythrocin (AE, AT, BH, CY, EG, GB, GR, IE, IQ, IR, JO, KR, LB, LK, LY, OM, PH, QA, SA, SY, TW, YE);</li>\n      <li>Erythrocine (NL);</li>\n      <li>Erythrodar (AE, BH, JO, KW, QA, SA);</li>\n      <li>Erythromil (AT, BE, BF, BG, BJ, CH, CI, CZ, DE, DK, EE, ET, FI, FR, GB, GH, GM, GN, GR, HN, IE, IT, KE, LR, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, PL, PT, RU, SC, SD, SE, SK, SL, SN, TN, TR, TZ, UG, ZM, ZW);</li>\n      <li>Erythromycin (DE);</li>\n      <li>Erythromycinum (NL);</li>\n      <li>Erythropen (GR);</li>\n      <li>Etocin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Etrocin (ZW);</li>\n      <li>Etrotab (MY);</li>\n      <li>Farmicina (UY);</li>\n      <li>Firmac (LK);</li>\n      <li>Hexabiotin (DK);</li>\n      <li>Ilosone (BR, KR, MX, PH, VE);</li>\n      <li>Indo-250 (ZW);</li>\n      <li>Narlecin (ID);</li>\n      <li>Panamicyn (CO);</li>\n      <li>Pantomicina (AR, CL, ES, PE, VE);</li>\n      <li>Pharothrocin (ID);</li>\n      <li>Primacine (IE, MT);</li>\n      <li>Rhythm (BD);</li>\n      <li>Roug-mycin (GR);</li>\n      <li>Rubimycin (ZA);</li>\n      <li>Ryebact (PH);</li>\n      <li>Rythocin (TH);</li>\n      <li>Rythrocaps (ZW);</li>\n      <li>Trovilon (ID);</li>\n      <li>Xin Hong Kang (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice bulletin No. 120: use of prophylactic antibiotics in labor and delivery,&quot; <i>Obstet Gynecol</i>, 2011, 117(6):1472-83. Available at<a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\"> http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/21606770/pubmed\" target=\"_blank\" id=\"21606770\">21606770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 160: premature rupture of membranes. <i>Obstet Gynecol</i>. 2016;127(1):e39-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/26695586 /pubmed\" target=\"_blank\" id=\"26695586 \">26695586 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines For Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camilleri M, Parkman HP, Shafi MA, et al, &quot;Clinical Guideline: Management of Gastroparesis,&quot; <i>Am J Gastroenterol,</i> 2013, 108(1):18-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/23147521/pubmed\" target=\"_blank\" id=\"23147521\">23147521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers  for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. <i>MMWR Recomm Rep</i>. 2009;58(RR-11):1-166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/19730409/pubmed\" target=\"_blank\" id=\"19730409\">19730409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chicella MF, Batres LA, Heesters MS, et al, &quot;Prokinetic Drug Therapy in Children: A Review of Current Options,&quot; <i>Ann Pharmacother</i>, 2005, 39(4):706-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/15755792/pubmed\" target=\"_blank\" id=\"15755792\">15755792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costalos C, Gounaris A, Varhalama E, et al, &quot;Erythromycin as a Prokinetic Agent in Preterm Infants,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 34(1):23-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11753159/pubmed\" target=\"_blank\" id=\"11753159\">11753159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curry JI, Lander TD, and Stringer MD, &quot;Review Article: Erythromycin as a Prokinetic Agent in Infants and Children,&quot; <i>Aliment Pharmacol Ther</i>, 2001, 15(5):595-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11328252/pubmed\" target=\"_blank\" id=\"11328252\">11328252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Lorenzo C, Lachman R, and Hyman PE, &ldquo;Intravenous Erythromycin for Postpyloric Intubation,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 1990, 11(1):45-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/2136585/pubmed\" target=\"_blank\" id=\"2136585\">2136585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichenfield LF, Krakowski AC, Piggott C, et al, &quot;Evidence-Based Recommendations For the Diagnosis and Treatment of Pediatric Acne,&quot; <i>Pediatrics</i>, 2013, 131 Suppl 3:S163-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/23637225/pubmed\" target=\"_blank\" id=\"23637225\">23637225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farrar HC, Walsh-Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. <i>Pediatr Infect Dis J</i>. 1993;12(8):688-691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/8018130 /pubmed\" target=\"_blank\" id=\"8018130 \">8018130 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LH, Berlin M, Tsur L, et al, &quot;The Safety of Macrolides During Lactation,&quot; <i>Breastfeed Med</i>, 2009, 4(4):197-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/19366316/pubmed\" target=\"_blank\" id=\"19366316\">19366316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. April 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed May 21, 2015</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jadcherla SR and Berseth CL, &quot;Effect of Erythromycin on Gastroduodenal Contractile Activity in Developing Neonates,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 34(1):16-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11753158/pubmed\" target=\"_blank\" id=\"11753158\">11753158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kiefer L, Rubin A, McCoy JB, et al, &quot;The Placental Transfer of Erythomycin,&quot; <i>Am J Obstet Gynecol</i>, 1955, 69(1):174-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knight-Madden J and Serjeant GR, &quot;Invasive Pneumococcal Disease in Homozygous Sickle Cell Disease: Jamaican Experience 1973-1997,&quot; <i>J Pediatr</i>, 2001, 138(1):65-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11148514/pubmed\" target=\"_blank\" id=\"11148514\">11148514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ng YY, Su PH, Chen JY, et al, &quot;Efficacy of Intermediate-Dose Oral Erythromycin on Very Low Birth Weight Infants With Feeding Intolerance,&quot; <i>Pediatr Neonatol</i>, 2012, 53(1):34-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/22348492/pubmed\" target=\"_blank\" id=\"22348492\">22348492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oei J and Lui K, &quot;A Placebo-Controlled Trial of Low-Dose Erythromycin to Promote Feed Tolerance in Preterm Infants,&quot; <i>Acta Paediatr</i>, 2001, 90(8):904-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/11529540/pubmed\" target=\"_blank\" id=\"11529540\">11529540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patole S, Rao S, and Doherty D, &quot;Erythromycin as a Prokinetic Agent in Preterm Neonates: A Systematic Review,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2005, 90(4):F301-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/15899929/pubmed\" target=\"_blank\" id=\"15899929\">15899929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Philipson A, Sabath LD, and Charles D, &quot;Erythromycin and Clindamycin Absorption and Elimination in Pregnant Women,&quot; <i>Clin Pharmacol Ther</i>, 1976, 19(1):68-77.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray WA, Murray KT, Meredith S, et al, &quot;Oral Erythromycin and the Risk of Sudden Death From Cardiac Causes,&quot; <i>N Engl J Med</i>, 2004, 351(11):1089-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/15356306/pubmed\" target=\"_blank\" id=\"15356306\">15356306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Red Book: 2009 Report of the Committee on Infectious Diseases</i>, 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid B, DiLorenzo C, Travis L, et al, &ldquo;Diabetic Gastroparesis Due to Postprandial Antral Hypomotility in Childhood,&rdquo; <i>Pediatrics</i>, 1992, 90(1 Pt 1):43-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/1614777/pubmed\" target=\"_blank\" id=\"1614777\">1614777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez L, Irani K, Jiang H, et al, &quot;Clinical presentation, Response to Therapy, and outcome of Gastroparesis in Children,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(2):185-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/22228004/pubmed\" target=\"_blank\" id=\"22228004\">22228004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rolain JM, Brouqui P, Koehler JE, et al, &ldquo;Recommendations for Treatment of Human Infections Caused by Bartonella Species,&rdquo; <i>Antimicrob Agents Chemother</i>, 2004, 48(6):1921-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/15155180/pubmed\" target=\"_blank\" id=\"15155180\">15155180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sims PJ, Waites KB, Crouse DT. Erythromycin lactobionate toxicity in preterm neonates.<i> Pediatr Infect Dis J</i>. 1994;13(2):164-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/8190550 /pubmed\" target=\"_blank\" id=\"8190550 \">8190550 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sorensen HT, Skriver MV, Pedersen L, et al, &quot;Risk of Infantile Hypertrophic Pyloric Stenosis After Maternal Postnatal Use of Macrolides,&quot; <i>Scand J Infect Dis</i>, 2003, 35(2):104-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stang H, &quot;Pyloric Stenosis Associated With Erythromycin Ingested Through Breastmilk,&quot; <i>Minn Med</i>, 1986, 69(11):669-70, 682.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al, &quot;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&quot; <i>Clin Infect Dis</i>, 2005, 41(10):1373-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiwari T, Murphy TV, and Moran J, &quot;Recommended Antimicrobial Agents for the Treatment and Postexposure Prophylaxis of Pertussis: 2005 CDC Guidelines,&quot; <i>MMWR</i>, 2005, 54(RR-14):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/16340941/pubmed\" target=\"_blank\" id=\"16340941\">16340941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanderhoof JA, Young R, Kaufman SS, et al, &quot;Treatment of cyclic vomiting in childhood with erythromycin,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 1995, 21(Suppl 1):S60-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/8708873/pubmed\" target=\"_blank\" id=\"8708873\">8708873</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waites KB, Sims PJ, Crouse DT, et al, &ldquo;Serum Concentrations of Erythromycin After Intravenous Infusion in Preterm Neonates Treated for <i>Ureaplasma urealyticum</i> Infection,&rdquo; <i>Pediatr Infect Dis J</i>, 1994, 13(4):287-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/8036045/pubmed\" target=\"_blank\" id=\"8036045\">8036045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al, &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waseem S, Islam S, Kahn G, et al, &quot;Spectrum of Gastroparesis in Children,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2012, 55(2):166-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/22314391/pubmed\" target=\"_blank\" id=\"22314391\">22314391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al, &ldquo;The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2006, 43(9):1089-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erythromycin-systemic-pediatric-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15977 Version 220.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8086256\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8086257\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10484225\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442462\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10485224\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8086458\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8086259\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10485264\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8086365\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10485164\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8085309\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8086286\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8086273\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8086274\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25872268\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8086288\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8086289\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8086293\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8086263\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8086264\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10485265\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8086369\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8086371\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8086461\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962015\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15977|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=erythromycin-systemic-drug-information\" class=\"drug drug_general\">Erythromycin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=erythromycin-systemic-patient-drug-information\" class=\"drug drug_patient\">Erythromycin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}